Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Hansa Biopharma Ord Shs HNSBF

Healthcare Biotechnology
Hansa Biopharma AB, formerly Hansa Medical AB, is a Sweden-based biopharmaceutical company with focus on immunomodulatory enzymes for treatment and prevention of rare and severe autoimmune conditions and transplant rejection. The Company’s operations consist of research and development for drug discovery. The Company conducts several projects, among which primary are IdeS (Immunoglobulin G... see more

Recent & Breaking News (GREY:HNSBF)

Hansa Biopharma Interim Report Jan-Mar 2020. EMA Process on Track; an Opinion From the CHMP is Expected in the Second Quarter 2020

PR Newswire April 28, 2020

Hansa Biopharma to Host Conference Call to Provide Interim Results for the First Quarter of 2020 and Business Update

PR Newswire April 15, 2020

Hansa Biopharma Announces Long Term Follow-up Data That Demonstrates 2-year Graft Survival of 89% After Imlifdase Treatment and Transplantation

PR Newswire March 6, 2020

Hansa Biopharma to Participate in Two Upcoming Investor Conferences

PR Newswire February 25, 2020

Hansa Biopharma Completes Enrollment in Anti-GBM

PR Newswire January 27, 2020

Hansa Biopharma to Host Conference Call to Provide Year-End report 2019 and Business Update

PR Newswire January 22, 2020

Hansa Biopharma Provides Business Update Ahead of the JP Morgan Global Healthcare Conference

PR Newswire January 12, 2020

Hansa Biopharma has Agreed With the FDA on a Regulatory Path Forward for Imlifidase in Kidney Transplantation of Highly Sensitized Patients in the U.S.

PR Newswire December 13, 2019

Hansa Biopharma Interim Report January-September 2019

PR Newswire October 31, 2019

Hansa Biopharma to Host Conference Call to Provide Interim Results for the First Nine Months of 2019 and Business Update

PR Newswire October 11, 2019

Hansa Biopharma Confirms Follow-up Meeting With FDA

PR Newswire September 25, 2019

Hansa Biopharma: Positive Results Presented at ESOT; Imlifidase Enabled Transplantation in 46 Sensitized Patients

PR Newswire September 18, 2019

Hansa Biopharma: New Imlifidase Data Presented at ESOT, Copenhagen

PR Newswire August 30, 2019

Hansa Biopharma to Participate in Three Upcoming Investor Conferences

PR Newswire August 21, 2019

Hansa Biopharma Interim Report January-June 2019

PR Newswire July 18, 2019

Plenary Presentation at the 2019 American Transplant Congress Demonstrates Significant Reduction in Time on the Waitlist for Patients Treated with Imlifidase Compared to Matched Controls

PR Newswire June 7, 2019

Hansa Biopharma to Participate in UBS Global Healthcare Conference and RBC Capital Markets Global Healthcare Conference in New York City

PR Newswire May 13, 2019

Hansa Biopharma Announces Upcoming Presentations at the 2019 American Transplant Congress

PR Newswire May 2, 2019

Notice to Annual General Meeting in Hansa Biopharma AB (publ)

PR Newswire April 17, 2019

Hansa Biopharma Receives Ethics and Regulatory Clearance to Start Phase 2 Study of Imlifidase in Guillain Barré Syndrome

PR Newswire April 15, 2019